title: Imatinib inhibition of fludarabine uptake in T-lymphocytes.
abstract: OBJECTIVE
  We investigated the potential drug-drug interaction between imatinib and fludarabine, which may be concomitantly administered in chronic myeloid leukemia (CML) patients receiving fludarabine-based conditioning for allogeneic hematopoietic cell transplantation (HCT). Imatinib is an inhibitor of human equilibrative transporters (hENTs), which are responsible for the intracellular uptake of fludarabine.
  
  
  METHODS
  Intracellular accumulation of fludarabine triphosphate (F-ara-ATP), the active metabolite of fludarabine, was measured in CD4(+) and CD8(+) T-lymphocytes isolated from healthy volunteers, which were treated in vitro with fludarabine alone, and in the presence of either imatinib or NBMPR, a known hENT inhibitor.
  
  
  RESULTS
  Imatinib significantly inhibited F-ara-ATP accumulation in CD4(+) and CD8(+) T-lymphocytes in a concentration-dependent manner. The observed imatinib inhibition was comparable to inhibition observed with NBMPR. The inhibition of F-ara-ATP by imatinib is likely due to inhibition of nucleoside transporters hENT1 and hENT2.
  
  
  CONCLUSIONS
  There is significant in vitro drug interaction between imatinib and fludarabine. This effect may be of important consideration in patients receiving fludarabine-based conditioning prior to HCT.
authors.affiliation: Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA.
authors.forename: Erica L
authors.initials: EL
authors.lastname: Woodahl
authors.forename: Joanne
authors.initials: J
authors.lastname: Wang
authors.forename: Shelly
authors.initials: S
authors.lastname: Heimfeld
authors.forename: Aaron G
authors.initials: AG
authors.lastname: Ren
authors.forename: Jeannine S
authors.initials: JS
authors.lastname: McCune
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D001549:Benzamides; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology*; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology*; D013868:Thioinosine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013868:Thioinosine; D000068877:Imatinib Mesylate; D014740:Vidarabine; C001789:4-nitrobenzylthioinosine; C024352:fludarabine